Latest Articles and Analysis

Louisiana directed a larger share of its opioid settlement to elected sheriffs than any other state — and required nothing in return. Three years of reporting confirm what that decision cost: millions spent on license-plate readers and defibrillators while the people the money was won for keep dying.

Being alive after addiction doesn't mean the system worked — it often means you got lucky. This National Recovery Month, CANN's Travis Roppolo draws on his own recovery from chemsex and stimulant use to map the gaps in trauma care, behavioral health parity, and stimulant treatment that keep survival a matter of privilege rather than policy.

On April 24, 2026, the Substance Abuse and Mental Health Services Administration (SAMHSA) issued a Dear Colleague letter that withdraws federal funding eligibility from fentanyl test strips, sterile...

Administration expands OUD medication access while defunding SAMHSA and restricting harm reduction.

Ukraine's integrated addiction care model outperforms U.S. fragmented approach despite war devastation and resource constraints.

Research proves alcohol doesn't reduce DAA efficacy for HCV, yet payers continue restricting treatment.

Opioid settlement funds risk misallocation; MAT gaps for minors and drug court issues identified.

DEA signals openness to telemedicine prescribing of controlled substances, expanding MAT access.

SAMHSA releases Harm Reduction Framework for federal substance use programming and community approaches.

Opioid settlement funds allocation overview: oversight and community impact considerations.

DEA proposed rules restrict telemedicine prescribing, harming rural patients and transgender individuals.

Xylazine contamination of drug supply demands harm reduction response including safe consumption sites.

Overdose Awareness Day calls for holistic interventions addressing SUD as a health issue, not criminal one.

Stigma drives opposition to harm reduction programs like safe consumption sites despite strong evidence.

Community-based low-barrier HCV treatment for PWID significantly improves liver health outcomes.

Conference examines HIV and methamphetamine use intersection among MSM and transgender communities.

CANN roundtable examines COVID-19 impacts on public health advocacy, Medicaid expansion, and HIV programs.

DOJ clarifies ADA protections for people with opioid use disorder against discrimination.

Medicaid sobriety restrictions on HCV treatment contradict harm reduction and elimination goals.

Family support predicts treatment success; policy must address intimate partner violence and health outcomes.